Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

Donald Kaufman, Derek Raghavan, Michael A Carducci, Ellis Glenn Levine, Barbara Murphy, Joseph Aisner, Timothy Kuzel, Steven Nicol, William Oh, Walter Stadler

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the activity and toxicity of the combination of gemcitabine and cisplatin in the treatment of chemotherapy-naive patients with metastatic urothelial cancer. Patients and Methods: Forty-six patients with measurable stage IV carcinoma of the urothelium were enrolled onto this trial. Gemcitabine 1,000 mg/m2 was administered intravenously for 30 to 60 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin was administered after gemcitabine on day 1 of each cycle. The first 11 patients received an initial cisplatin dose of 100 mg/m2. Due to the hematologic toxicity observed in several of these patients, the dose was reduced to 75 mg/m2 in the remaining 35 patients. Patients were treated with six cycles, unless disease progression or severe toxicity necessitated earlier discontinuation. Results: Ten of the 46 patients achieved a complete response and nine showed a partial response. The overall response rate was 41%. The median time to treatment failure was 5.5 months. The median survival was 14.3 months, and the 1-year survival probability was 54%. Most of the toxicities were hematologic and, in general, easily manageable. Conclusion: Gemcitabine plus cisplatin is active in the treatment of metastatic urothelial cancer in chemotherapy-naive patients and has an acceptable clinical safety profile. Studies are under way to further define the place of gemcitabine in combination with other chemotherapeutic agents in the treatment of metastatic urothelial cancer. (C) 2000 by American Society of Clinical Oncology.

Original languageEnglish (US)
Pages (from-to)1921-1927
Number of pages7
JournalJournal of Clinical Oncology
Volume18
Issue number9
StatePublished - May 2000

Fingerprint

gemcitabine
Cisplatin
Neoplasms
Drug Therapy
Urothelium
Survival
Treatment Failure

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kaufman, D., Raghavan, D., Carducci, M. A., Levine, E. G., Murphy, B., Aisner, J., ... Stadler, W. (2000). Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal of Clinical Oncology, 18(9), 1921-1927.

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. / Kaufman, Donald; Raghavan, Derek; Carducci, Michael A; Levine, Ellis Glenn; Murphy, Barbara; Aisner, Joseph; Kuzel, Timothy; Nicol, Steven; Oh, William; Stadler, Walter.

In: Journal of Clinical Oncology, Vol. 18, No. 9, 05.2000, p. 1921-1927.

Research output: Contribution to journalArticle

Kaufman, D, Raghavan, D, Carducci, MA, Levine, EG, Murphy, B, Aisner, J, Kuzel, T, Nicol, S, Oh, W & Stadler, W 2000, 'Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer', Journal of Clinical Oncology, vol. 18, no. 9, pp. 1921-1927.
Kaufman D, Raghavan D, Carducci MA, Levine EG, Murphy B, Aisner J et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal of Clinical Oncology. 2000 May;18(9):1921-1927.
Kaufman, Donald ; Raghavan, Derek ; Carducci, Michael A ; Levine, Ellis Glenn ; Murphy, Barbara ; Aisner, Joseph ; Kuzel, Timothy ; Nicol, Steven ; Oh, William ; Stadler, Walter. / Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 9. pp. 1921-1927.
@article{d7c3543762344a108a19e326c8f4ff48,
title = "Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer",
abstract = "Purpose: To assess the activity and toxicity of the combination of gemcitabine and cisplatin in the treatment of chemotherapy-naive patients with metastatic urothelial cancer. Patients and Methods: Forty-six patients with measurable stage IV carcinoma of the urothelium were enrolled onto this trial. Gemcitabine 1,000 mg/m2 was administered intravenously for 30 to 60 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin was administered after gemcitabine on day 1 of each cycle. The first 11 patients received an initial cisplatin dose of 100 mg/m2. Due to the hematologic toxicity observed in several of these patients, the dose was reduced to 75 mg/m2 in the remaining 35 patients. Patients were treated with six cycles, unless disease progression or severe toxicity necessitated earlier discontinuation. Results: Ten of the 46 patients achieved a complete response and nine showed a partial response. The overall response rate was 41{\%}. The median time to treatment failure was 5.5 months. The median survival was 14.3 months, and the 1-year survival probability was 54{\%}. Most of the toxicities were hematologic and, in general, easily manageable. Conclusion: Gemcitabine plus cisplatin is active in the treatment of metastatic urothelial cancer in chemotherapy-naive patients and has an acceptable clinical safety profile. Studies are under way to further define the place of gemcitabine in combination with other chemotherapeutic agents in the treatment of metastatic urothelial cancer. (C) 2000 by American Society of Clinical Oncology.",
author = "Donald Kaufman and Derek Raghavan and Carducci, {Michael A} and Levine, {Ellis Glenn} and Barbara Murphy and Joseph Aisner and Timothy Kuzel and Steven Nicol and William Oh and Walter Stadler",
year = "2000",
month = "5",
language = "English (US)",
volume = "18",
pages = "1921--1927",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

AU - Kaufman, Donald

AU - Raghavan, Derek

AU - Carducci, Michael A

AU - Levine, Ellis Glenn

AU - Murphy, Barbara

AU - Aisner, Joseph

AU - Kuzel, Timothy

AU - Nicol, Steven

AU - Oh, William

AU - Stadler, Walter

PY - 2000/5

Y1 - 2000/5

N2 - Purpose: To assess the activity and toxicity of the combination of gemcitabine and cisplatin in the treatment of chemotherapy-naive patients with metastatic urothelial cancer. Patients and Methods: Forty-six patients with measurable stage IV carcinoma of the urothelium were enrolled onto this trial. Gemcitabine 1,000 mg/m2 was administered intravenously for 30 to 60 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin was administered after gemcitabine on day 1 of each cycle. The first 11 patients received an initial cisplatin dose of 100 mg/m2. Due to the hematologic toxicity observed in several of these patients, the dose was reduced to 75 mg/m2 in the remaining 35 patients. Patients were treated with six cycles, unless disease progression or severe toxicity necessitated earlier discontinuation. Results: Ten of the 46 patients achieved a complete response and nine showed a partial response. The overall response rate was 41%. The median time to treatment failure was 5.5 months. The median survival was 14.3 months, and the 1-year survival probability was 54%. Most of the toxicities were hematologic and, in general, easily manageable. Conclusion: Gemcitabine plus cisplatin is active in the treatment of metastatic urothelial cancer in chemotherapy-naive patients and has an acceptable clinical safety profile. Studies are under way to further define the place of gemcitabine in combination with other chemotherapeutic agents in the treatment of metastatic urothelial cancer. (C) 2000 by American Society of Clinical Oncology.

AB - Purpose: To assess the activity and toxicity of the combination of gemcitabine and cisplatin in the treatment of chemotherapy-naive patients with metastatic urothelial cancer. Patients and Methods: Forty-six patients with measurable stage IV carcinoma of the urothelium were enrolled onto this trial. Gemcitabine 1,000 mg/m2 was administered intravenously for 30 to 60 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin was administered after gemcitabine on day 1 of each cycle. The first 11 patients received an initial cisplatin dose of 100 mg/m2. Due to the hematologic toxicity observed in several of these patients, the dose was reduced to 75 mg/m2 in the remaining 35 patients. Patients were treated with six cycles, unless disease progression or severe toxicity necessitated earlier discontinuation. Results: Ten of the 46 patients achieved a complete response and nine showed a partial response. The overall response rate was 41%. The median time to treatment failure was 5.5 months. The median survival was 14.3 months, and the 1-year survival probability was 54%. Most of the toxicities were hematologic and, in general, easily manageable. Conclusion: Gemcitabine plus cisplatin is active in the treatment of metastatic urothelial cancer in chemotherapy-naive patients and has an acceptable clinical safety profile. Studies are under way to further define the place of gemcitabine in combination with other chemotherapeutic agents in the treatment of metastatic urothelial cancer. (C) 2000 by American Society of Clinical Oncology.

UR - http://www.scopus.com/inward/record.url?scp=17444437833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444437833&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 1921

EP - 1927

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -